Stifel Reiterates Hold Rating on Biogen (BIIB), Notes CMS Decision "Closes The Door" for Aduhelm Coverage
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating on Biogen (NASDAQ: BIIB), following the final CMS coverage decision for beta ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
